Market open

Kodiak Sciences/$KOD

14:30

22:10

05:45

13:25

21:00

1D1W1MYTD1Y5YMAX

About Kodiak Sciences

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Ticker

$KOD

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Palo Alto, United States

Employees

108

Website

kodiak.com

Kodiak Sciences Metrics

BasicAdvanced

$399M

-

-$3.65

2.25 -

Price and volume

Market cap

$399M

Beta

2.25

52-week high

$11.42

52-week low

$2.19

Average daily volume

498K

Financial strength

Current ratio

8.416

Quick ratio

8.224

Long term debt to equity

34.115

Total debt to equity

39.615

Management effectiveness

Return on assets (TTM)

-27.71%

Return on equity (TTM)

-78.57%

Valuation

Price to book

2.15

Price to tangible book (TTM)

2.15

Price to free cash flow (TTM)

-2.712

Growth

Earnings per share change (TTM)

-29.63%

3-year earnings per share growth (CAGR)

-5.62%

What the Analysts think about Kodiak Sciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.

Kodiak Sciences Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Kodiak Sciences Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Kodiak Sciences News

AllArticlesVideos

Eye-Disease Focused Kodiak Sciences Is A Promising 'Turnaround Story For 2025': Analyst Upgrades Stock

Benzinga·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $KOD

$

Capital at risk

Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kodiak Sciences stock?

Kodiak Sciences (KOD) has a market cap of $399M as of January 15, 2025.

What is the P/E ratio for Kodiak Sciences stock?

The price to earnings (P/E) ratio for Kodiak Sciences (KOD) stock is 0 as of January 15, 2025.

Does Kodiak Sciences stock pay dividends?

No, Kodiak Sciences (KOD) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Kodiak Sciences dividend payment date?

Kodiak Sciences (KOD) stock does not pay dividends to its shareholders.

What is the beta indicator for Kodiak Sciences?

Kodiak Sciences (KOD) has a beta rating of 2.25. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.